Jan Geliebter, Ph.D., has had an interest in science since the age of eight, when his parents bought him a chemistry set. Following postdoctoral training in the molecular genetics of the Major Histocompatibility Complex with Dr. Stanley Nathenson at the Albert Einstein College of Medicine, Dr. Geliebter's career has focused on the molecular pathogenesis and immunology of cancer, as well as immunological diseases.
Over the last 20 years, with the help of supportive chairs, supportive faculty, and graduate students, Dr. Geliebter has been the director of the medical microbiology course for second-year medical students. During this time, he has maintained an active research laboratory and mentored residents, graduate students, medical students, M.D.-Ph.D. students, undergraduate students, and high school students.
Education
- Ph.D., Microbiology and Immunology, State University of New York (SUNY) Downstate Medical Center
- B.Sc., Biology, Hebrew University of Jerusalem
Honors and Awards
- Member, Alpha Omega Alpha Medical Honor Society
- NYMC Teaching and Mentoring Award, 2002, 2004, 2006, 2007, 2008, 2009, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018, 2019, 2020, 2021
- NYMC Student Senate Award, 2014, 2017, 2018
- Robert Goldstein Society of Teachers Award, 2014
- AMWA Gender Equity Award, 2004
Research
Dr. Geliebter's laboratory uses RNASeq to interrogate the landscape of gene expression alteration in PTC in clinical samples. By comparing PTC and samples of normal tissues from the same patients, the researchers have gained insight into the molecular changes driving PTC, as well as potential therapeutic targets. As men have a lower incidence of PTC than women, the lab is concentrating on the role of androgens in the etiology and progression of PTC. The results indicate that androgens exert an anti-proliferative effect and result in a G1-S block in the cancer cell cycle.
Publications
- Carnazza M, Werner R, Begley M, et. al. "Traditional Chinese Medicine for Pediatric Allergic Diseases." Current allergy and asthma reports, 25(1), (2025) 33. doi: 10.1007/s11882-025-01208-7
- Taico Oliva C, Musa I, Ardalani F, et. al. "Cannabinoid Derived Product is a Potential Novel Therapeutic for Papillary Thyroid Carcinoma." Integrative cancer therapies, 24(), (2025) 15347354251332966. doi: 10.1177/15347354251332966
- Carnazza M, Quaranto D, DeSouza N, et. al. "The Current Understanding of the Molecular Pathogenesis of Papillary Thyroid Cancer." International journal of molecular sciences, 26(10), (2025) . doi: 10.3390/ijms26104646
- Maskey AR, Carnazza M, Spears M, et. al. "Berberine Suppression of Human IgE but Not IgG Production via Inhibition of STAT6 Binding Activity at IgE Promoter by BCL6." Cells, 14(8), (2025) . doi: 10.3390/cells14080591
- Klausner MS, Greenberg CA, Noruzi KA, et. al. "The Role of M6A LncRNA Modification in Papillary Thyroid Cancer." International journal of molecular sciences, 26(7), (2025) . doi: 10.3390/ijms26072833
- Maskey AR, Sasaki A, Sargen M, et. al. "Breaking the cycle: a comprehensive exploration of topical steroid addiction and withdrawal." Frontiers in allergy, 6(), (2025) 1547923. doi: 10.3389/falgy.2025.1547923
- Carnazza M, Werner R, Tiwari RK, et. al. "The Etiology of IgE-Mediated Food Allergy: Potential Therapeutics and Challenges." International journal of molecular sciences, 26(4), (2025) . doi: 10.3390/ijms26041563
Teaching Responsibilities
- Medical Microbiology
- Basic Immunology
- Advanced Immunology
- Immunopharmacology
- Introduction to Pathology
- Dental Microbiology
- Transition to Clerkship
- Transition to Fourth Year
- COVID-19 Bootcamp
